Athenex (ANTX) IPO Opens 9% Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Athenex, Inc. Announces Pricing of Initial Public Offering
June 14, 2017 7:01 AM EDTBUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $11.00 per share. In addition, Athenex has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price. The company's shares are expected to begin trading on The NASDAQ Global Select Market on June 14, 2017 under... More
